 |
|
Nutrient Synergy
– A Specific Formulation of Nutrients Containing Lysine,
Proline, Ascorbic Acid, and Epigallocatechin Gallate Inhibits
Matrix Metalloproteinases Activity and Invasion Potential of Human
Cancer Cell Lines (2002)
Room MW, Netke SP, Ivanov V, Niedzwiecki A, Rath
M.
Presented at: European Organization
for Research and Treatment of Cancer (EORTC), AACR and NCI Symposium
on Molecular Targets and Cancer Therapeutics
Frankfurt, Germany, Nov. 19-22, 2002
Published in: European Cancer
Journal, 38, Suppl.7/Abs.280, 2002
Abstract
Introduction:
One of the hallmarks of cancer is its ability
to invade and metastasize to distal organs. Matrix metalloproteinases
(MMPs) have been identified as key players in tumor invasion and
metastasis. Excessive MMP secretion has been regarded as an index
of malignancy, which leads to the degradation of extracellular
matrix. Current treatment protocols with chemotherapy and/or radiation,
although beneficial, are toxic and have the potential to destroy
healthy cells as well. Our approach has been to develop strategies
to inhibit cancer development, progression and metastasis using
naturally occurring nutrients, which are relatively non-toxic.
Lysine and proline are building blocks of collagen fibers that
stabilize connective tissue by inhibiting the enzymatic digestion
of collagen fibers. Vitamin C is essential for production of collagen
and acts as a powerful antioxidant by scavenging free radicals
and thereby protects cells from damage. Epigallocatechin gallate
(EGCG) is a green tea extract with antioxidant and anticancerogenic
properties. It prevents cancer cell invasion by inhibiting MMPs.
It is postulated that the combination of these nutrients would
exert a very potent synergistic anticancer activity. Based on
the above hypothesis, Nutrient Synergy (NS), a mixture of nutrients
such as lysine, proline, ascorbic acid and EGCG, was formulated
by Dr. Rath Research Institute.
Objective:
In the present study, we investigated the effect of NS on MMP
expression, matrix invasion potential and cell proliferation in
several human cancer lines those of skin (melanoma), breast (MDA
MB-231) and liver (Hep G2). We also studied the effects of NS
on normal human dermal fibroblast (NHDF) and on a co-culture of
melanoma and NHDF cells.
Methods and Materials:
MMP expression was studied by zymography, extracellular matrix
invasion by using reconstituted basement membrane (Matrigel) and
cytotoxicity/cell proliferation by MTT assay.
Results:
NS inhibited the expression of both MMP-2 and MMP-9 in a dose
dependent fashion. The expression of both MMP -2 and –9
were significantly inhibited with a concentration of 100 µg/ml
of NS and virtually undetectable with a concentration of 1000
µg/ml. NS used at 10 and 100 µg/ml concentrations
did not significantly affect cells viability and at 1000 µg/ml
it showed cytotoxicity at the range of 10-40% depending on the
cell type. The invasion of melanoma cells through Matrigel matrices
was inhibited by 20% and 100% at 10 and 50 µg/ml respectively.
Similar invasion of MDA MB-231 was also reduced by 50%, 60% and
95% at 10, 50 and 100 µg/ml respectively. When melanoma
cells were co-cultured with NHDF cells, NS inhibited the invasion
by 30% and 100% with 10 and 50 µg/ml, respectively.
Conclusions:
Thus, these results demonstrate that NS is very effective for
several cancer cell lines and also in co-culture in inhibiting
the expression of MMPs and preventing cellular invasion through
Matrigel. These observations revealed that NS may provide a natural
therapeutic basis, which makes it a valuable and promising candidate
for the treatment of human cancers. Currently, experiments are
in progress to evaluate the efficacy of NS in a clinical setting.
Comment:
These results demonstrated that the synergistic effect of
ascorbic acid, lysine, proline, and epigallocatechin gallate
significantly inhibited metastasis potential of human melanoma,
breast and liver cancer cells by inhibiting the expression
of MMPs and Matrigel invasion, suggesting this non-toxic agent
as a promising candidate for the treatment of human cancers.
|


|
|
 |